Advanced in Chromosome 13q Deletion

Diane K. Wherrett

Toronto, ON, CA 
Advanced in Chromosome 13q Deletion
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Diane Wherrett practices in Toronto, Canada. Ms. Wherrett is rated as an Advanced expert by MediFind in the treatment of Chromosome 13q Deletion. Her top areas of expertise are Type 1 Diabetes (T1D), Chromosome 13q Deletion, Intersex, and Mixed Gonadal Dysgenesis.

Her clinical research consists of co-authoring 46 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Chromosome 13q Deletion.

Gender
Female

Locations

Toronto, ON, Canada
Other Locations
M5G1X8, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes
Enrollment Status: Completed
Publish Date: June 06, 2024
Intervention Type: Drug
Study Drug: CTLA4-Ig (Abatacept)
Study Phase: Phase 2
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Terminated
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
AntiCD3 Mab (Teplizumab) For Prevention of Diabetes In Relatives At-Risk for Type 1 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: August 05, 2020
Intervention Type: Drug
Study Phase: Phase 2
Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1
Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1
Enrollment Status: Completed
Publish Date: July 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

44 Total Publications

Protocol for the development of a core outcome set for type 1 diabetes risk screening.
Protocol for the development of a core outcome set for type 1 diabetes risk screening.
Journal: BMJ open
Published: June 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Wherrett's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile